Vivos Therapeutics, Inc.

NasdaqCM:VVOS Stok Raporu

Piyasa değeri: US$16.3m

Vivos Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Vivos Therapeutics CEO'su R. Huntsman, Sep2016 tarihinde atandı, in görev süresi 8.17 yıldır. in toplam yıllık tazminatı $ 657.70K olup, şirket hissesi ve opsiyonları dahil olmak üzere 70.5% maaş ve 29.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.53% ine doğrudan sahiptir ve bu hisseler $ 250.57K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 4.4 yıldır.

Anahtar bilgiler

R. Huntsman

İcra Kurulu Başkanı

US$657.7k

Toplam tazminat

CEO maaş yüzdesi70.5%
CEO görev süresi8.2yrs
CEO sahipliği1.5%
Yönetim ortalama görev süresi2.8yrs
Yönetim Kurulu ortalama görev süresi4.4yrs

Son yönetim güncellemeleri

Recent updates

Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Nov 12
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

Sep 10
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Apr 25
It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Feb 02
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Apr 18
Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Vivos Therapeutics again delays Q2 2022 results

Aug 23

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

Jun 29

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

May 21
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

Vivos Therapeutics: First Take After The Broad Market Sell-Off

Mar 06

CEO Tazminat Analizi

R. Huntsman'un ücretlendirmesi Vivos Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$13m

Jun 30 2024n/an/a

-US$12m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$658kUS$463k

-US$14m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$20m

Dec 31 2022US$938kUS$385k

-US$24m

Sep 30 2022n/an/a

-US$25m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$22m

Dec 31 2021US$1mUS$344k

-US$20m

Sep 30 2021n/an/a

-US$24m

Jun 30 2021n/an/a

-US$21m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$455kUS$252k

-US$18m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$11m

Mar 31 2020n/an/a

-US$12m

Dec 31 2019US$328kUS$249k

-US$12m

Dec 31 2018US$284kUS$249k

-US$9m

Tazminat ve Piyasa: R. 'ın toplam tazminatı ($USD 657.70K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 646.00K ).

Tazminat ve Kazançlar: R. 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

R. Huntsman (66 yo)

8.2yrs

Görev süresi

US$657,701

Tazminat

Mr. R. Kirk Hunstman is the Co-Founder of Vivos Therapeutics, Inc. since September 2016 and has been its Chief Executive Officer and Director since September 2016 and has been its Chairman of the Board sin...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
R. Huntsman
Co-Founder8.2yrsUS$657.70k1.53%
$ 250.6k
Bradford Amman
CFO, Treasurer & Secretary6.1yrsUS$400.04k0.0017%
$ 274.6
Todd Huntsman
Co-Founder & Senior VP of Product and Technologyless than a yearVeri yokVeri yok
RaeAnn Byrnes
Co-Founder and Senior VP of Events & Clinical Advisory Servicesno dataVeri yokVeri yok
Susan McCullough
Co-Founder & Executive VP of Operationsless than a yearVeri yokVeri yok
Nicholas DeGennaro
Senior Vice President of Medical Integration Division5.1yrsVeri yokVeri yok
Ruth Hembree
Senior Vice President of Practice Servicesno dataVeri yokVeri yok
Stephanie Huebner
Senior Vice President of Dental Service Integration2.8yrsVeri yokVeri yok
John Ballard
Senior Vice President of Technologyless than a yearVeri yokVeri yok

2.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: VVOS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
R. Huntsman
Co-Founder8.2yrsUS$657.70k1.53%
$ 250.6k
Leonard Sokolow
Independent Director4.4yrsUS$63.00k0.0084%
$ 1.4k
Anja Krammer
Independent Director4.4yrsUS$58.00k0%
$ 0
Mark Lindsay
Independent Director4.4yrsUS$58.00k0%
$ 0
Matthew Thompson
Independent Director4.4yrsUS$63.00k0%
$ 0
Edward Zuckerberg
Member of Medical & Clinical Advisory Board3.8yrsVeri yokVeri yok
Ralph Green
Independent Director4.4yrsUS$58.00k0%
$ 0
Michael Gelb
Member of Medical & Clinical Advisory Board3.8yrsVeri yokVeri yok
Manisha Witmans
Member of Medical & Clinical Advisory Board3.8yrsVeri yokVeri yok
Tammarie Heit
Member of Medical & Clinical Advisory Board3.8yrsVeri yokVeri yok
Clete Kushida
Co-Chair of Medical & Clinical Advisory Board3.8yrsVeri yokVeri yok
Cecilia Wu
Co-Chair of Medical & Clinical Advisory Boardno dataVeri yokVeri yok

4.4yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VVOS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).